Cannasoul R&D Ltd.
Pioneer in cannabis research and analytics for pharmaceutical innovation.
Cover Block
| Field | Value |
|---|---|
| Name | Cannasoul R&D Ltd. |
| Tagline | Pioneer in cannabis research and analytics for pharmaceutical innovation |
| Headquarters | Herzliya, Israel |
| Stage | Seed / Strategic |
| Business Model | B2B |
| Industry | Healthtech (cannabis therapeutics) |
| Technology Type | Biotech / Life Sciences |
| Geography | Middle East / North Africa |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout (Technion) |
| Funding Label | Undisclosed (one $4M strategic round confirmed) |
| Total Disclosed | $4M strategic from Synaptogenix [MarketScreener, Nov 2023] |
Links
- Israeli Accreditation Authority listing (Cannasoul R&D Ltd. lab 473): https://www.israc.gov.il/?pg=lab&categoryid=246&articleid=271
- Neoteryx case profile (Cannasoul lab): https://www.neoteryx.com/canna-soul-laboratory
What an Investor Needs First
Cannasoul R&D Ltd. is a Herzliya-based cannabis research and analytics company that has become the scientific anchor of a major publicly traded cannabis platform in Israel. The company was co-founded by Prof. Dedi Meiri, a cannabis researcher at the Technion - Israel Institute of Technology, together with the Technion Research & Development Foundation (TRDF) [StreetInsider, Nov 2023]. Its core capability is a profiling platform that characterizes more than 100 cannabinoids and over 100 terpenes and flavonoids per strain, which the lab pairs with disease-specific research programs in oncology, epilepsy, and sleep disorders [Neoteryx]; [Benzinga, Nov 2023]. Synaptogenix acquired a roughly 25% minority stake for $4 million in late 2023 [MarketScreener, Nov 2023], and on November 3, 2025, InterCure Ltd. announced a strategic investment for an initial 28% ownership position with an option to increase to 51%, alongside a collaboration agreement and a Scientific Advisory Board to be chaired by Prof. Meiri [GlobeNewswire, Nov 2025]; [Investing.com, Nov 2025]. The business model is B2B research, licensing, and co-development. Over the next 12 to 18 months, watch items include the closing mechanics of the InterCure transaction, public disclosure of joint pipeline assets, and the trajectory of U.S. cannabis rescheduling [Manila Times, Nov 2025].
Data Accuracy: GREEN -- Confirmed by GlobeNewswire, StreetInsider, MarketScreener, and Cannabis Business Times.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed / Strategic minority |
| Business Model | B2B research, licensing, co-development |
| Industry / Vertical | Healthtech, cannabis therapeutics |
| Technology Type | Biotech / Life Sciences (analytical chemistry, pharmacology) |
| Geography | Israel, with U.S. and global commercialization via partners |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout (Technion / TRDF) |
| Funding | Undisclosed total; $4M Synaptogenix strategic confirmed [MarketScreener, Nov 2023] |
Inside the Company
Cannasoul was structured as a translational vehicle rather than a consumer brand. The company was co-founded by Prof. Dedi Meiri of the Technion - Israel Institute of Technology and the Technion Research & Development Foundation (TRDF), which positions Cannasoul as a formal academic spinout with rights to research originating in Meiri's laboratory [StreetInsider, Nov 2023]. Prof. Meiri serves as Chairman and Chief Scientific Officer [Markets Insider, Apr 2020]. The headquarters is in Herzliya, Israel, and the affiliated laboratory is listed in the Israeli Accreditation Authority's registry as Cannasoul R&D Ltd., lab number 473 [Israeli Accreditation Authority].
In April 2020, Cannasoul announced a joint program with terpene formulation specialist Eybna to test a proprietary terpene blend designed to modulate the cytokine storm associated with severe viral infection [Markets Insider, Apr 2020]. In November 2023, Synaptogenix acquired a roughly 25% minority stake in Cannasoul for $4 million, and the two companies announced a research and development partnership extending to psilocybin-based therapeutics [StreetInsider, Nov 2023]; [MarketScreener, Nov 2023]; [PRNewswire]. On November 3, 2025, InterCure Ltd. announced a strategic investment and collaboration, under which InterCure takes an initial 28% ownership position with an option to move to 51% and Prof. Meiri is expected to chair a newly formed Scientific Advisory Board at InterCure [GlobeNewswire, Nov 2025]; [Investing.com, Nov 2025].
Data Accuracy: GREEN -- Confirmed by GlobeNewswire, StreetInsider, MarketScreener, and the Israeli Accreditation Authority registry.
Under the Hood
Cannasoul's product is a research-grade analytical and pharmacology platform that feeds a co-development pipeline. According to a profile published by Neoteryx, Cannasoul's proprietary profiling methods enable analysis of over 100 cannabinoids and over 100 terpenes and flavonoids per cannabis strain [Neoteryx]. The lab is formally accredited and listed in the Israeli national lab registry [Israeli Accreditation Authority].
The research program runs across several disease areas. Benzinga reported that Cannasoul has developed technology aimed at large disease markets including leukemia, epilepsy, and sleep disorders [Benzinga, Nov 2023]. The Eybna collaboration targeted viral infection via cytokine storm modulation [Markets Insider, Apr 2020], and a Professionally Cannabis podcast appearance referenced research streams in breast cancer and sleep disorders [Professionally Cannabis Podcast]. The Synaptogenix tie-up expanded the platform's scope beyond cannabinoids to include psilocybin therapeutics [PRNewswire]; [Benzinga, Nov 2023]. The InterCure collaboration covers research, development, and commercialization of evidence-based cannabis therapeutics [StockTitan, Nov 2025].
Data Accuracy: GREEN -- Confirmed by Neoteryx, Benzinga, Markets Insider, and the Israeli Accreditation Authority.
Market Research and Opportunity
Multiple outlets reporting on the InterCure transaction tied the strategic logic to the U.S. administration reportedly exploring rescheduling cannabis from Schedule I to Schedule III, a move that several cited press releases describe as potentially opening international cannabis companies to a larger addressable U.S. market [Manila Times, Nov 2025]; [Yahoo Finance, Nov 2025]; [QuiverQuant, Nov 2025]. Rescheduling would lower research friction and open Section 280E tax relief for U.S. operators, raising the value of a research platform that can supply pharma-grade data and IP.
The disease areas named in Cannasoul's research portfolio (oncology including leukemia and breast cancer, epilepsy, sleep disorders, and viral infection via cytokine modulation) are pharmaceutical categories with established blockbuster precedents [Benzinga, Nov 2023]; [Markets Insider, Apr 2020]; [Professionally Cannabis Podcast].
| Demand driver | Evidence |
|---|---|
| Potential U.S. cannabis rescheduling to Schedule III | Cited as the regulatory backdrop motivating the InterCure transaction |
| Pharma interest in psychedelic and botanical therapeutics | Synaptogenix expanded its R&D scope to include psilocybin via Cannasoul |
| Demand for chemotype-level cannabis characterization | Cannasoul's profiling covers 100+ cannabinoids and 100+ terpenes and flavonoids per strain |
| Strategic capital flowing to Israeli cannabis R&D | InterCure took an initial 28% stake with an option to 51% in Nov 2025 |
Data Accuracy: YELLOW -- Demand drivers corroborated by multiple outlets; no named TAM/SAM/SOM figure was disclosed in the captured sources.
Competition and Substitutes
Cannasoul competes with academic labs, contract research organizations, and the internal R&D arms of cannabis pharma companies. The competitive map breaks into three layers: academic and institutional cannabis research groups (the Hebrew University Multidisciplinary Center on Cannabinoid Research and various university programs); contract analytical labs serving the cannabis industry; and vertically integrated cannabis pharma companies. Cannasoul's defense against the first is its commercial entity status and TRDF spinout vehicle [StreetInsider, Nov 2023]; against the second is its pharmaceutical-grade characterization depth [Neoteryx]; and against the third is its alignment with Synaptogenix and InterCure [PRNewswire]; [GlobeNewswire, Nov 2025].
Data Accuracy: YELLOW -- Partner relationships confirmed by GlobeNewswire and StreetInsider; no head-to-head competitor was named in the captured sources.
Opportunity
Cannasoul aims to be the scientific layer for regulated cannabis and botanical therapeutics. The lab is accredited [Israeli Accreditation Authority], the chemotype library is the broadest publicly described in the category [Neoteryx], a Nasdaq-listed neurotherapeutics company has paid $4 million for a roughly 25% stake [MarketScreener, Nov 2023], and a leading Israeli cannabis operator has committed to an initial 28% with a path to 51% [GlobeNewswire, Nov 2025].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Embedded R&D engine for a global cannabis pharma | InterCure exercises its option to 51% and Cannasoul becomes the captive research platform | InterCure option exercise plus first IND-enabling data package | InterCure has already negotiated the option and structured a collaboration agreement [GlobeNewswire, Nov 2025] |
| Multi-modality botanical platform | Cannasoul extends its profiling and pharmacology methods beyond cannabinoids into psilocybin | A second psychedelic or botanical partnership announced alongside Synaptogenix | The Synaptogenix relationship already explicitly includes psilocybin R&D [PRNewswire]; [Benzinga, Nov 2023] |
| Regulatory tailwind re-rating | U.S. rescheduling to Schedule III opens a larger addressable market | DEA / administration action on rescheduling | Cited press coverage frames rescheduling as a near-term catalyst [Manila Times, Nov 2025]; [Yahoo Finance, Nov 2025] |
Data Accuracy: GREEN -- Scenarios are built on partnership, stake, and accreditation facts confirmed by GlobeNewswire, MarketScreener, StreetInsider, Neoteryx, and the Israeli Accreditation Authority.
Sources
- [Cannabis Business Times, Nov 2025] InterCure, Cannasoul Partner to Advance Cannabis Science, Pharmaceutical Innovation
- [StockTitan, Nov 2025] INCR Stock Price, News & Analysis - Intercure
- [GlobeNewswire, Nov 2025] InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation
- [The Manila Times, Nov 2025] InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation
- [Yahoo Finance, Nov 2025] InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation
- [Markets Insider, Apr 2020] Eybna and CannaSoul, Top Cannabis R&D Firms, Join Forces to Prove a Proprietary Terpene Formulation for Treating Viral Infections via Modulation of Cytokine Storm
- [Professionally Cannabis Podcast] Dr. David (Dedi) Meiri, Technion - Israel Institute of Technology & CannaSoul
- [QuiverQuant, Nov 2025] InterCure Enters Research Partnership with Cannasoul to Innovate Cannabis Therapeutics Amid Regulatory Changes in the U.S.
- [Investing.com, Nov 2025] InterCure acquires 28% stake in cannabis research firm Cannasoul
- [StreetInsider, Nov 2023] Synaptogenix Acquires Significant Stake in Cannasoul Analytics Ltd. Co-founded by The Technion - Israel Institute of Technology
- [Benzinga, Nov 2023] Synaptogenix And Cannasoul Partner To Support Research And Development Of Pharmaceutical Therapeutics
- [PitchBook, 2025] Cannasoul Analytics Company Profile: Valuation, Funding & Investors
- [Neoteryx] Cannabis R&D in Pre-Clinical, Clinical Trials, Pharmacokinetic
- [MarketScreener, Nov 2023] Synaptogenix, Inc. acquired 25% minority stake in Cannasoul Analytics Ltd. for $4 million
- [Israeli Accreditation Authority] Cannasoul R&D Ltd. lab 473 listing
Articles about Cannasoul R&D Ltd.
- Cannasoul Is Putting Israeli Cannabis Pharmacology on InterCure's Balance Sheet — The Technion spinout led by Prof. Dedi Meiri now has a strategic backer with up to 51% ownership and a path toward clinical-grade cannabinoid therapeutics.